{"id":573259,"date":"2025-10-29T00:00:00","date_gmt":"2025-10-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2025-biopharma-multiple-myeloma-disease-landscape-forecast-g7-2025\/"},"modified":"2026-03-31T10:24:35","modified_gmt":"2026-03-31T10:24:35","slug":"dlsfon0005-2025-biopharma-multiple-myeloma-disease-landscape-forecast-g7-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2025-biopharma-multiple-myeloma-disease-landscape-forecast-g7-2025\/","title":{"rendered":"Multiple Myeloma | Disease Landscape &#038; Forecast | G7 | 2025"},"content":{"rendered":"<p>The treatment of multiple myeloma is becoming increasingly complex. Sanofi&#8217;s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible patients, in combination with bortezomib, lenalidomide, and dexamethasone. The regimen will directly compete with regimens containing Johnson &#038; Johnson\u2019s Darzalex or Darzalex Faspro \/ Darzquro. The approval of bispecific antibodies (e.g., Johnson &#038; Johnson\u2019s Tecvayli and Talvey, Pfizer\u2019s Elrexfio) and the label expansion of CAR T-cell therapies (e.g., Bristol Myers Squibb \/ Bluebird Bio\u2019s Abecma, Johnson &#038; Johnson \/ Legend Biotech\u2019s Carvykti) have expanded the options available for relapsed \/ refractory disease. GSK\u2019s antibody-drug conjugate Blenrep and other therapies in late-phase development will, if approved, further fragment the treatment of multiple myeloma.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What are the sizes of the key drug-treatable populations? How will drug-treatment rates change over the 2024-2034 forecast period?<\/li>\n<li>How will the current treatment landscape change over the forecast period, and what impact will generic entry have on the market?<\/li>\n<li>Which emerging therapies are the most promising for multiple myeloma?<\/li>\n<li>What factors are driving the growth of the multiple myeloma therapy market, and how will it evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-573259","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-myeloma","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573259\/revisions"}],"predecessor-version":[{"id":575300,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573259\/revisions\/575300"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}